Dasabuvir, ombitasvir, paritaprevir and ritonavir;
Viekira pak (TN)

(Dasabuvir sodium hydrate [DR:D10581] | Dasabuvir [DR:D10553]), (Ombitasvir hydrate [DR:D10598] | Ombitasvir [DR:D10576]), (Paritaprevir hydrate [DR:D10597] | Paritaprevir [DR:D10580]), Ritonavir [DR:D00427]

Antiviral

Dasabuvir is an inhibitor of UGT1A1 and P-glycoprotein (P-gp). It is metabolized by CYP2C8 and it is a substrate for P-glycoprotein (P-gp).
Ombitasvir is an inhibitor of UGT1A1, and it is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Paritaprevir is an inhibitor of UGT1A1, and it is an inhibitor of the following transporters: OATP1B1 and OATP1B3. It is metabolized by CYP3A4 and it is a substrate for P-glycoprotein (P-gp).
Ritonavir is an inhibitor of CYP3A4 and P-glycoprotein (P-gp). It is metabolized by CYP3A and it is a substrate for P-glycoprotein (P-gp).

HCV NS3/4A protease [KO:K22273 K22274]
HCV NS5A [KO:K22275]
HCV NS5B [KO:K22472]
RNA-directed DNA polymerase

Enzyme: CYP3A [HSA:1576 1577 1551], CYP2C8 [HSA:1558]
Transporter: SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCB1 [HSA:5243], ABCG2 [HSA:9429]

CYP inhibition: CYP3A4 [HSA:1576]
Transporter inhibition: SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
Enzyme inhibition: UGT1A1 [HSA:54658]
DDI search